filmze.rip Traffic Analytics & Website Stats
filmze.rip is a domain having .rip extension. filmze.rip is a arts and entertainment/tv movies and streaming website. filmze.rip gets 94,972 traffic per month, the site is estimated to be worth $10,858.00. Over the last three months, filmze.rip's global ranking has decreased from 200,477 to 364,128. filmze.rip's traffic has decreased by 30.44% compared to last month, which is already a sign. Which countries sent the most traffic to filmze.rip lately? Last month France was the top country sending traffic to filmze.rip. filmze.rip's audience is 63.99% male and 36.01% female. The largest age group of visitors are 18 - 24 year olds.
- Traffic Report
-
Monthly Unique Visitors:
15,081
-
Monthly Pageviews:
94,972
- Estimated Valuation
-
Income Per Day:
$ 23
-
Estimated Worth:
$ 10,858
- Geography & Country Targeting
-
Countries Total Count:
9
-
Hot Country & Region:
France
- Search keywords & Backlinks
-
Keywords Total Count:
85
-
Backlinks Sites:
2
- Global Ranks
-
Global Rank:
364,128
-
Country Rank:
678
- Global Rank Change
-
Global Rank Change:
-121,431
-
Country Rank Change:
-669
- Web Information
- HTTP Information
- Whois Information
Web Server Information
-
Hosted IP Address:
104.21.53.247
-
Hosted Country:
US
-
Location Latitude:
39.043701171875
-
Location Longitude:
-77.474197387695
Page Title of filmze.rip
Regarder Film Streaming et Séries VOSTFR Gratuitement Complet | Filmze
Meta Description of filmze.rip
Filmze est une plateforme gratuite pour regarder des films et des séries en VOSTFR.
Meta Tags of filmze.rip
Film streaming HD Serie streaming Filmze Streaming Complet Film streaming film gratuit streaming vf Series VOSTFR
Website Inpage Analysis
-
H1 Headings:
0
-
H2 Headings:
0
-
H3 Headings:
0
-
H4 Headings:
0
-
H5 Headings:
0
-
H6 Headings:
0
-
Total IFRAMEs:
0
-
Total Images:
53
-
Total Forms:
1
-
Total Scripts:
9
-
Google Adsense:
No Data
-
Google Analytics:
No Data
HTTP Header Analysis
Date: Wed, 04 Jan 2023 09:17:58 GMT
Content-Type: text/html; charset=utf-8
Transfer-Encoding: chunked
Connection: keep-alive
expires: Thu, 19 Nov 1981 08:52:00 GMT
cache-control: no-store, no-cache, must-revalidate
pragma: no-cache
vary: Accept-Encoding
CF-Cache-Status: DYNAMIC
Server: cloudflare
CF-RAY: 7842e257afa59803-SJC
Content-Encoding: gzip
alt-svc: h3=":443"; ma=86400, h3-29=":443"; ma=86400
Full WHOIS Lookup
Registry Domain ID: 21002d97aadf4a2f9a8dfccb9f950475-DONUTS
Registrar WHOIS Server: whois.dynadot.com
Registrar URL: http://dynadot.com
Updated Date: 2022-02-09T16:50:53Z
Creation Date: 2022-02-04T16:50:13Z
Registry Expiry Date: 2023-02-04T16:50:13Z
Registrar: Dynadot, LLC
Registrar IANA ID: 472
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +1.6502620100
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Registry Registrant ID: REDACTED FOR PRIVACY
Registrant Name: REDACTED FOR PRIVACY
Registrant Organization:
Registrant Street: REDACTED FOR PRIVACY
Registrant City: REDACTED FOR PRIVACY
Registrant State/Province: California
Registrant Postal Code: REDACTED FOR PRIVACY
Registrant Country: US
Registrant Phone: REDACTED FOR PRIVACY
Registrant Phone Ext: REDACTED FOR PRIVACY
Registrant Fax: REDACTED FOR PRIVACY
Registrant Fax Ext: REDACTED FOR PRIVACY
Registrant Email: Please query the RDDS service of the Registrar of Record identified in this output for information on how to contact the Registrant, Admin, or Tech contact of the queried domain name.
Registry Admin ID: REDACTED FOR PRIVACY
Admin Name: REDACTED FOR PRIVACY
Admin Organization: REDACTED FOR PRIVACY
Admin Street: REDACTED FOR PRIVACY
Admin City: REDACTED FOR PRIVACY
Admin State/Province: REDACTED FOR PRIVACY
Admin Postal Code: REDACTED FOR PRIVACY
Admin Country: REDACTED FOR PRIVACY
Admin Phone: REDACTED FOR PRIVACY
Admin Phone Ext: REDACTED FOR PRIVACY
Admin Fax: REDACTED FOR PRIVACY
Admin Fax Ext: REDACTED FOR PRIVACY
Admin Email: Please query the RDDS service of the Registrar of Record identified in this output for information on how to contact the Registrant, Admin, or Tech contact of the queried domain name.
Registry Tech ID: REDACTED FOR PRIVACY
Tech Name: REDACTED FOR PRIVACY
Tech Organization: REDACTED FOR PRIVACY
Tech Street: REDACTED FOR PRIVACY
Tech City: REDACTED FOR PRIVACY
Tech State/Province: REDACTED FOR PRIVACY
Tech Postal Code: REDACTED FOR PRIVACY
Tech Country: REDACTED FOR PRIVACY
Tech Phone: REDACTED FOR PRIVACY
Tech Phone Ext: REDACTED FOR PRIVACY
Tech Fax: REDACTED FOR PRIVACY
Tech Fax Ext: REDACTED FOR PRIVACY
Tech Email: Please query the RDDS service of the Registrar of Record identified in this output for information on how to contact the Registrant, Admin, or Tech contact of the queried domain name.
Name Server: diva.ns.cloudflare.com
Name Server: christian.ns.cloudflare.com
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of WHOIS database: 2023-01-17T10:53:40Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
Terms of Use: Identity Digital Inc. provides this Whois service for information purposes, and to assist persons in obtaining information about or related to a domain name registration record. Identity Digital does not guarantee its accuracy. Users accessing the Identity Digital Whois service agree to use the data only for lawful purposes, and under no circumstances may this data be used to: a) allow, enable, or otherwise support the transmission by e-mail, telephone, or facsimile of mass unsolicited, commercial advertising or solicitations to entities other than the registrar's own existing customers and b) enable high volume, automated, electronic processes that send queries or data to the systems of Identity Digital or any ICANN-accredited registrar, except as reasonably necessary to register domain names or modify existing registrations. When using the Identity Digital Whois service, please consider the following: The Whois service is not a replacement for standard EPP commands to the SRS service. Whois is not considered authoritative for registered domain objects. The Whois service may be scheduled for downtime during production or OT&E maintenance periods. Queries to the Whois services are throttled. If too many queries are received from a single IP address within a specified time, the service will begin to reject further queries for a period of time to prevent disruption of Whois service access. Abuse of the Whois system through data mining is mitigated by detecting and limiting bulk query access from single sources. Where applicable, the presence of a [Non-Public Data] tag indicates that such data is not made publicly available due to applicable data privacy laws or requirements. Should you wish to contact the registrant, please refer to the Whois records available through the registrar URL listed above. Access to non-public data may be provided, upon request, where it can be reasonably confirmed that the requester holds a specific legitimate interest and a proper legal basis for accessing the withheld data. Access to this data can be requested by submitting a request via the form found at https://www.identity.digital/about/policies/whois-layered-access/ Identity Digital Inc. reserves the right to modify these terms at any time. By submitting this query, you agree to abide by this policy.
Similarly Ranked Websites
-
Find your favorite Movie or TV show right now! Find the latest and greatest to the classics. Action Kungfu movies, Romantic chick flicks, Thrillers that will have you on the edge of your seat, all for you to enjoy on your PC, Mobile or tablet.
just-watch.club 128,207 -
Regarder vos animes en ligne, regardez des animes VF et VOSTFR en ligne. Toutvostfr regarder anime vf en streaming gratuitement.
toutvostfr.com 114,971 -
Nikos Pekiaridis/NurPhoto via Getty Images(NEW YORK) -- Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday. The phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said. The follow-up period for each participant will be six months. "By combining both indications in one vaccine approach, we aim to provide individuals with an efficient way to receive immunization against two severe respiratory diseases with evolving viruses that require vaccine adaptation," Dr. Ugur Sahin, CEO and co-founder of BioNTech, said in a statement. The combination vaccine is based on the currently available bivalent COVID-19 booster and a quadrivalent mRNA flu vaccine, which is designed to protect against four different flu viruses. The phase 1 trial will test for safety, immune response and optimal dose level of the combination vaccine, before moving on to larger trials. The data will also provide insight into the potential of mRNA vaccines to address more than one pathogen, Sahin said. Annaliesa Anderson, senior vice president and chief scientific officer of vaccine research and development for Pfizer, called this an "exciting step in our ongoing journey with BioNTech as we collectively look to transform the prevention of infectious diseases around the world." "Even with existing seasonal influenza vaccines, the burden of this virus is severe across the world causing thousands of deaths and hospitalizations every year," she said in a statement. Studies indicate COVID-19 vaccine efficacy fades over time, though it's not clear if every American will need an annual COVID-19 booster. As scientists continue to assess the need, several companies are at work on creating a single injection each fall that protects against both seasonal flu and COVID-19. In addition to Pfizer, pharmaceutical companies Moderna and Novavax have announced plans to work on a combo shot. Moderna said it anticipates starting clinical trials on a single-dose vaccine that combines a booster against COVID-19 and a booster against flu by the end of the year, with hopes of the vaccine being available for the 2023 season. "We believe this is a very large opportunity that is ahead of us, if we could bring to market a high efficacy pan-respiratory annual booster," Moderna COE Stéphane Bancel said during the Sept. 9 investor meeting. Last year, Novavax enrolled people in a Phase 1/2 study to evaluate the safety, tolerability and immune response of a combination vaccine using the company's seasonal influenza and COVID-19 vaccines. A phase 2 confirmation trial is expected to begin later this year, the company said in October. Copyright © 2022, ABC Audio. All rights reserved.
mycentraloregon.com 1,173,413 -
Sur BlueSeries, vous trouverez un nombre illimité de séries en streaming VF et VOSTFR, gratuitement, des séries complètes sans limites et sans inscription.
blueseries.net 290,251